SANOFI-AVENTIS BEATS FORECASTS

A A

Sanofi-Aventis beat third-quarter forecasts as the French pharmaceuticals company's older heart disease and cancer drugs, as well as influenza vaccines continued to sell well. Net income rose 29 per cent to €1.92bn ($2.27bn), excluding acquisition costs associated with Sanofi's takeover of Aventis last year and sales rose 12 per cent to €7.2bn. Shares rose 2.8 per cent by mid-day to €69.80 as Sanofi's results beat analysts' expectations.

MSNBC (http://msnbc.msn.com/id/9966220/)